Ayman Al-Hendy to Genetic Therapy
This is a "connection" page, showing publications Ayman Al-Hendy has written about Genetic Therapy.
Connection Strength
5.511
-
Magnetic nanoparticles as a new approach to improve the efficacy of gene therapy against differentiated human uterine fibroid cells and tumor-initiating stem cells. Fertil Steril. 2016 06; 105(6):1638-1648.e8.
Score: 0.436
-
Targeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma. Reprod Sci. 2016 Apr; 23(4):464-74.
Score: 0.432
-
Enhancing Adenoviral-Mediated Gene Transfer and Expression to Endometrial Cells. Reprod Sci. 2016 08; 23(8):1109-15.
Score: 0.432
-
Towards gene therapy of postoperative adhesions: fiber and transcriptional modifications enhance adenovirus targeting towards human adhesion cells. Gynecol Obstet Invest. 2013; 76(2):119-24.
Score: 0.363
-
Toward gene therapy of premature ovarian failure: intraovarian injection of adenovirus expressing human FSH receptor restores folliculogenesis in FSHR(-/-) FORKO mice. Mol Hum Reprod. 2010 Apr; 16(4):241-50.
Score: 0.284
-
Gene therapy of benign gynecological diseases. Adv Drug Deliv Rev. 2009 Aug 10; 61(10):822-35.
Score: 0.271
-
Towards fibroid gene therapy: adenovirus-mediated delivery of herpes simplex virus 1 thymidine kinase gene/ganciclovir shrinks uterine leiomyoma in the Eker rat model. Gynecol Obstet Invest. 2009; 68(1):19-32.
Score: 0.268
-
Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model. Fertil Steril. 2010 Jan; 93(1):239-50.
Score: 0.265
-
Toward gene therapy of endometriosis: transductional and transcriptional targeting of adenoviral vectors to endometriosis cells. Am J Obstet Gynecol. 2008 Aug; 199(2):117.e1-6.
Score: 0.256
-
Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells. Hum Reprod. 2008 Mar; 23(3):514-24.
Score: 0.247
-
Toward gene therapy of primary ovarian failure: adenovirus expressing human FSH receptor corrects the Finnish C566T mutation. Mol Hum Reprod. 2008 Jan; 14(1):9-15.
Score: 0.245
-
Adenovirus-mediated delivery of a dominant-negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007 Oct; 92(10):3949-57.
Score: 0.238
-
Toward gene therapy of endometriosis: adenovirus-mediated delivery of dominant negative estrogen receptor genes inhibits cell proliferation, reduces cytokine production, and induces apoptosis of endometriotic cells. Fertil Steril. 2007 Aug; 88(2):462-71.
Score: 0.233
-
Inhibition of growth of cervical cancer cells using a dominant negative estrogen receptor gene. Gynecol Oncol. 2007 Feb; 104(2):276-80.
Score: 0.228
-
Gene therapy of uterine leiomyoma: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells in vitro and in a nude mouse model. Gynecol Obstet Invest. 2007; 63(2):61-70.
Score: 0.225
-
Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006 Jul-Aug; 12(4):385-400.
Score: 0.218
-
Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004 Nov; 191(5):1621-31.
Score: 0.198
-
Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol. 2000 Mar; 182(3):553-9.
Score: 0.143
-
Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest. 1997; 43(4):268-75.
Score: 0.115
-
Mutant MMP-9 and HGF gene transfer enhance resolution of CCl4-induced liver fibrosis in rats: role of ASH1 and EZH2 methyltransferases repression. PLoS One. 2014; 9(11):e112384.
Score: 0.099
-
Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomas. Hum Reprod. 2013 Sep; 28(9):2398-406.
Score: 0.090
-
Low-dose simultaneous delivery of adenovirus encoding hepatocyte growth factor and vascular endothelial growth factor in dogs enhances liver proliferation without systemic growth factor elevation. Liver Int. 2009 Aug; 29(7):1022-30.
Score: 0.068
-
Abrogation of estrogen receptor signaling augments cytotoxicity of anticancer drugs on CaSki cervical cancer cells. Anticancer Res. 2008 Jul-Aug; 28(4B):2181-7.
Score: 0.064
-
Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 1996 Jun 15; 87(12):5095-103.
Score: 0.028
-
Growth retardation--an unexpected outcome from growth hormone gene therapy in normal mice with microencapsulated myoblasts. Hum Gene Ther. 1996 Jan; 7(1):61-70.
Score: 0.027
-
Correction of the growth defect in dwarf mice with nonautologous microencapsulated myoblasts--an alternate approach to somatic gene therapy. Hum Gene Ther. 1995 Feb; 6(2):165-75.
Score: 0.025
-
Environmental risk factors for prevention and molecular intervention of cervical cancer. Int J Hyg Environ Health. 2007 Dec; 210(6):671-678.
Score: 0.014